NanOlogy

Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. NanOlogy has now progressed investigational drugs based on the technology into clinical research across multiple solid tumors. Marc helped establish NanOlogy in 2015 to advance tumor-directed drug therapy. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. Paul is Chairman and CEO of NanOlogy and DFB Pharmaceuticals. In 1990, Paul and two partners founded DFB growing annual sales from $18 million to more than $400 million across multiple companies, with operations in Texas, New Jersey, Germany, and Canada.